Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com -- Lantheus Holdings Inc (NASDAQ:LNTH) stock rose 2.5% Wednesday following the announcement of an exclusive licensing agreement with GE HealthCare (NASDAQ:GEHC) for its prostate cancer diagnostic imaging agent in Japan.
Under the agreement, GE HealthCare will develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (marketed as PYLARIFY in the U.S.) in Japan for prostate cancer diagnostics and companion diagnostic use. The deal includes the transfer of regulatory dossiers, manufacturing competencies, and technical support to enable GE HealthCare to drive clinical development toward potential regulatory submissions and commercial launch in Japan.
GE HealthCare will leverage its manufacturing network and R&D expertise following its March 2025 acquisition of Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan. This partnership aims to address a significant market need, as Japan recorded the third highest number of prostate cancer cases globally in 2022, after the U.S. and China.
"This partnership is expected to meaningfully extend the reach of our diagnostic imaging agent in key international markets," said Brian Markison, CEO of Lantheus.
The financial terms include an upfront license fee, development milestones, and tiered royalties based on product sales in Japan. The companies will establish a Joint Steering Committee to oversee development and commercialization activities.
PYLARIFY, FDA-approved in 2021, has been used in over 500,000 scans across 48 states in the U.S. and received European approval in 2023, where it is marketed as PYLCLARI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.